Back to Top Skip to main content

DoD, FDA working together to benefit warfighters

Dr. Scott Gottlieb, FDA Commissioner (left) and Mr. Thomas McCaffery, Principal Deputy Assistant Secretary of Defense (Health Affairs) (right), congratulate on another following the signing of a memorandum of understanding between the DoD and the FDA.  The ceremony acknowledges the existing partnership and the future collaboration on accessing life-saving medical products for U.S. troops on the battlefield. Dr. Scott Gottlieb, FDA Commissioner (left) and Mr. Thomas McCaffery, Principal Deputy Assistant Secretary of Defense (Health Affairs) (right), congratulate one another following the signing of a memorandum of understanding between the DoD and the FDA. The ceremony acknowledges the existing partnership and the future collaboration on accessing life-saving medical products for U.S. troops on the battlefield.

Recommended Content:

Health Readiness

In a move to better serve the unique needs of the nation’s warfighters, leaders from the U.S. Food and Drug Administration and the Office of the Assistant Secretary of Defense for Health Affairs signed a memorandum of understanding to foster and prioritize the development of critical medical products.

The signing of the memorandum formalizes the partnership between the FDA and the Department of Defense that was authorized under a law enacted by Congress in 2017. Under this law, DoD is able to request help in speeding up development and review of products used to diagnose, treat, or prevent serious or life-threatening diseases and conditions faced by service members. It also allows for emergency use of medical products for threats that pose a specific risk to service members, including biological, chemical, radiological, or nuclear agents.

The FDA will continue to work with DoD to evaluate how to best access medical products that serve the military’s medical needs and rush review of priority DoD medical products. The FDA will also provide advice for the development and manufacturing of these products, and examine those that are already under development to determine which will streamline review.

The memorandum directs specific actions between the agencies, including semi-annual meetings at the senior-leader levels, quarterly meetings with FDA centers, and collaborations on emergency use of products.

Dr. Terry Rauch, acting deputy assistant secretary of Defense for Health Readiness Policy and Oversight, said the memorandum enables the Military Health System to speak through one voice with the FDA on strategic issues and to move forward on urgent needs with a prioritized DoD list for the FDA to focus on.

“DoD and FDA have always been committed to safe and effective products for our service members, and this [memorandum] really solidifies the needed relationship to provide these most effectively,” said Rauch. “We have already seen increased readiness due to the collaborative efforts with the approval of three medical products since the release of the law.”

The FDA has approved the use of an auto-injector for nerve agent exposure, a prophylactic drug for malaria, and the RECELL system for point-of-care skin regeneration in trauma patients. These products were approved after the release of the law, and the memorandum strengthens these efforts even further, he said.

“These products are critical to warfighter readiness in deployed environments and to the far-forward care settings that we face,” said Rauch. “Battlefield trauma and prolonged field care are at the forefront of challenges in military medicine.”

Earlier this year, the FDA granted emergency use authorization for DoD’s use of freeze-dried plasma. Rauch described it as a life-saving product designed for austere environments, which can now be used in a much more streamlined process under the authorization. In addition, the FDA approved a new malaria prophylactic drug, tafenoquine, in August.

“The FDA has been incredibly helpful and forward-leaning with all aspects of interaction on DoD medical product development,” said Rauch. “We are grateful that there is an increased interest by the leadership to drive collaboration, and we are leveraging that interest to the fullest.”

You also may be interested in...

DHA IPM 19-003: Reserve Health Readiness Program

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) through (c), and in accordance with the guidance of References (d) through (i): • Provides utilization guidance and funding requirements for the RHRP contract to supplement Reserve Component Individual Medical Readiness (IMR) and Deployment Health activities when Service organic health readiness resources are not available to meet mission requirements. • Provides utilization guidance and funding requirements for the RHRP contract for Active Duty enrolled in TRICARE Prime Remote, U.S. Coast Guard (USCG), USCG Reserves, and re-deploying DoD civilians (e.g., U.S. Army Corps of Engineers and U.S. Army Intelligence and Security Command). • Communicate procedure guidance to all DoD organizations utilizing RHRP services. • Will expire effective 12 months from the date of issue and be converted to a DHA-Procedural Instruction.

  • Identification #: 19-003
  • Date: 3/8/2019
  • Type: DHA Interim Procedures Memorandum
  • Topics: Health Readiness

DHA PI 6025.07: Naloxone in the MTFs

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) through (c), and in accordance with the guidance of References (d) through (h), establishes the Defense Health Agency’s (DHA) procedures for prescribing and dispensing naloxone by pharmacists in MTFs to eligible beneficiaries, upon beneficiary request, or when the pharmacist determines the beneficiary meets the established criteria for being at risk for a life-threatening opiate overdose.

DHA PI 6200.05: Force Health Protection Quality Assurance (FHPQA) Program

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (ab), establishes the procedures for the FHPQA Program as defined in Reference (z). This DHA-PI applies to: a. OSD, the Military Departments (including the United States Coast Guard (USCG) at all times, including when it is a Service in the Department of Homeland Security by agreement with that Department), the Office of the Chairman of the Joint Chiefs of Staff (CJCS) and the Joint Staff, the Combatant Commands, the Office of the Inspector General of the DoD, the Defense Agencies, the DoD Field Activities, and all other organizational entities within the DoD (referred to collectively in this DHA-PI as the “DoD Components”). b. Civilian personnel, as defined in Reference (e), and DoD contractor personnel authorized to accompany the force (CAAF), in accordance with References (j), (m), and (n), respectively.

  • Identification #: DHA PI 6200.05
  • Date: 5/2/2018
  • Type: DHA Procedural Instruction
  • Topics: Health Readiness

DoD Instruction 6200.05: Force Health Protection Quality Assurance (FHPQA) Program

Policy

This issuance establishes policy, assigns responsibilities, and defines requirements for the development and establishment of the FHPQA Program in accordance with the authority in DoD Directive (DoDD) 5124.02, Sections 731 and 738 of Public Law 108-375; Sections 1074f, 1092a, and 1073b of Title 10, United States Code; and DoDDs 6200.04 and 5136.13.

DoD Instruction 6490.13: Comprehensive Policy on Traumatic Brain Injury-Related Neurocognitive Assessments by the Military Services

Policy

This instruction establishes policy, assigns responsibilities, and prescribes standard elements, pursuant to section 722 of Public Law 111-383, requiring the implementation of a comprehensive neurocognitive assessment policy in the Military Services.

Embedded Fragment Analyses

Policy

Clarification of the Requirement for Continuation of Semi-Annual Reporting of Results of Embedded Fragment Analyses

Detecting and Reporting DoD Cases of Ebola Virus Disease Infection

Policy

Guidance as of 17 OCT 2014 from the Department of Defese (AFHSC)for Detecting and Reporting DoD Cases of Ebola Virus Disease Infection

Influenza Surveillance Program

Policy

Sentinel Sites for the 2014-2015 Influenza Surveillance Program

Deployment Limiting Mental Disorders and Psychotrophic Medications

Policy

Policy memorandum about Deployment Limiting Mental Disorders and Psychotrophic Medications

DoD Laboratories Participating in CDC Laboratory Response Network 03-213

Policy

Department of Defense (DoD) laboratories participating in the Centers for Disease Control and Prevention-sponsored Laboratory Response Network (LRN) do so with the approval and support of their respective Military Department Surgeons General.

  • Identification #: 03-213
  • Date: 3/26/2013
  • Type: Memorandums
  • Topics: Health Readiness

Medical Planning and Programming Lexicon

Policy

DoD Instruction Number 6490.11: DoD Policy Guidance for Management of Mild Traumatic Brain Injury/Concussion in the Deployed Setting

Policy

This instruction establishes policy, assigns responsibilities, and provides procedures on the management of mild traumatic brain injury (mTBI), also known as concussion, in the deployed setting.

Access to Medical Services Who were Exposed to Rabies in Combat Theater

Policy

U.S. Navy/U.S. Marine Corps COSC Policy Update

Policy

Mental Health Assessments for Members of the Armed Forces Deployed in Connection with a Contingency Operation

Policy
<< < 1 2 > >> 
Showing results 1 - 15 Page 1 of 2

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.